Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Osteosarcoma, FIERCe Trial

• Status: NOT_YET_RECRUITING
• Trial end date: 2044-01-31

Summary

This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 ST chimeric antigen receptor (CAR) T cells and how well they work in treating patients with osteosarcoma that recurred or spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they attack tumor cells. T cells are taken from a patient's blood through a process called apheresis. Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells, such as FOLR1, is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by an intravenous infusion. Chemotherapy drugs, such as fludarabine and cyclophosphamide, are given to a patient before the manufactured FH-FOLR1 ST CAR T cells to make room for the CAR T cells in the blood and to enhance the CAR T cell activity in the patient. FH-FOLR1 ST CAR T cells may be safe, tolerable, and/or effective in treating patients with advanced osteosarcoma.

• Phase: PHASE1

Details

• Lead Sponsor: Fred Hutchinson Cancer Center
• Collaborator: Washington Research Foundation
• Treatments: Biopsy; Cyclophosphamide; fludarabine; Leukapheresis; Magnetic Resonance Spectroscopy